Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449991 | 0.85 | USP2 (0.41) | USP2SMN1; SMN2ALDH1A1HDAC6MAPT | |
| SCHEMBL1058528 | 0.81 | MAPT (0.39) | USP2SMN1; SMN2ALDH1A1HDAC6MAPT | |
| SCHEMBL2906720 | 0.79 | MAPT (0.39) | USP2SMN1; SMN2ALDH1A1HDAC6MAPT | |
| SCHEMBL3801396 | 0.78 | RECQL (0.38) | USP2SMN1; SMN2ALDH1A1HDAC6MAPT | |
| SCHEMBL1058529 | 0.78 | ALDH1A1 (0.39) | USP2SMN1; SMN2ALDH1A1HDAC6MAPT | |
| SCHEMBL2435292 | 0.78 | MAPT (0.38) | USP2SMN1; SMN2ALDH1A1HDAC6MAPT | |
| SCHEMBL1058524 | 0.77 | MAPT (0.38) | USP2SMN1; SMN2ALDH1A1HDAC6MAPT | |
| SCHEMBL2435295 | 0.77 | MAPT (0.37) | USP2SMN1; SMN2ALDH1A1HDAC6MAPT | |
| SCHEMBL2438216 | 0.76 | MAPT (0.37) | USP2SMN1; SMN2ALDH1A1HDAC6MAPT | |
| SCHEMBL2438222 | 0.75 | MAPT (0.36) | USP2SMN1; SMN2ALDH1A1HDAC6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | ABBVIE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8653141-B2 | HIV protease inhibiting compounds | ABBVIE INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2264032-B1 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBVIE INC (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| EP-2216334-B1 | HIV protease inhibiting sulfonamides | ABBOTT LAB (US) | 2012-10-31 | — | — | EP | disclosed |
| US-8193227-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2012-06-05 | — | — | US | disclosed |
| EP-1697348-B1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-1697344-B1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110003827-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2011-01-06 | — | — | US | disclosed |
| EP-2266971-A2 | Hiv protease inhibiting compounds | Abbott Laboratories (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-1709037-A2 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBOTT LABORATORIES (US) | 2006-10-11 | — | — | EP | disclosed |
| EP-1697348-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1697344-A2 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050159469-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2005-07-21 | — | — | US | disclosed |
| WO-2005061450-A2 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBOTT LABORATORIES (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005061487-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050148623-A1 | Prevent reproduct of aids virus | ABBVIE INC. | 2005-07-07 | — | — | US | disclosed |
| WO-2005058841-A2 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131042-A1 | HIV protease inhibiting compounds | ABBOTT LABORATORIES | 2005-06-16 | — | — | US | disclosed |
| US-20050131017-A1 | HIV protease inhibiting compounds | ABBOTT LABORATORIES | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003827-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | USP2 707/4885SMN1; SMN2 4444/4885ALDH1A1 2920/4885 |
| US-20050148623-A1 | Prevent reproduct of aids virus | SERPINB1, PRSS1, SERPINA3 | USP2 1989/4885SMN1; SMN2 4019/4885ALDH1A1 1209/4885 |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | SERPINB1, HPN, DNPEP | USP2 707/4885SMN1; SMN2 4444/4885ALDH1A1 2920/4885 |
| US-20050159469-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | USP2 707/4885SMN1; SMN2 4444/4885ALDH1A1 2920/4885 |
| US-20050131017-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | USP2 707/4885SMN1; SMN2 4444/4885ALDH1A1 2920/4885 |
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | SERPINB1, HPN, DNPEP | USP2 707/4885SMN1; SMN2 4444/4885ALDH1A1 2920/4885 |
| US-20050131042-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | USP2 707/4885SMN1; SMN2 4444/4885ALDH1A1 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.